Additionally, the occurrence of immune related adverse events due to anti-PD-1 therapy, including rheumatic diseases such as RA, SLE and pSS [25], further emphasizes a link between the PD-1 pathway and rheumatic diseases. Here, PDCD1 is linked to systemic lupus erythematosus.